Prosetta Biosciences

San Francisco, United States Founded: 2003 • Age: 23 yrs
Antiviral therapeutics are developed via a proprietary drug discovery platform.

About Prosetta Biosciences

Prosetta Biosciences is a Healthcare company based in San Francisco (United States) founded in 2003. Antiviral therapeutics are developed via a proprietary drug discovery platform. Prosetta Biosciences has raised $35.14 million across 7 funding rounds from investors including Takeda Pharmaceuticals, HHS and Alger. Its Indian entity Prosetta Bio-Conformatics Private Limited reported revenue of β‚Ή1.18 Cr. Prosetta Biosciences offers products and services including Small Molecule Therapeutics. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Viral. Its competitors include Moderna, Adaptive Biotechnologies and Novavax; 2 of its 3 listed competitors have raised funding.

Company details

Developer of antiviral and other therapeutics using proprietary drug discovery platform. The companys research is based on its proprietary cell-free protein synthesis or CFPSS drug discovery platform allows for the identification of small molecule drugs, which may be missed by traditional pharma screening methods. The company has successfully produced potent compounds which display activity against multiple strains of many viral families including lead series of molecules that are effective antiviral agents against influenza, HIV, and HCV.

Operational Areas
Key Metrics
  • Indian entity revenue
    ₹1.18 Cr

    FY 2024 · -11% YoY

  • Indian entity net profit
    ₹10.3 Lakh

    FY 2024 · 9% margin

  • Indian entity EBITDA
    ₹28.5 Lakh

    FY 2024 · 24% margin

  • Total Equity Funding
    $35.14M (USD)

    in 7 rounds

  • Latest Funding Round
    $31.1M (USD), Series D

    Nov 2015

  • Investors

Products & Services of Prosetta Biosciences

Prosetta Biosciences offers a comprehensive portfolio of products and services, including Small Molecule Therapeutics.

Small Molecule Therapeutics
Biopharmaceuticals

Advances novel molecules to modulate protein complexes for disease therapy

Funding Insights of Prosetta Biosciences

Prosetta Biosciences has successfully raised a total of $35.14M across 7 strategic funding rounds. The most recent funding activity was a Series D round of $31.1 million completed in November 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $35.14M
  • Total Rounds 7
  • Last Round Series D β€” $31.1M
  • First Round $2M

    (May 2007)

  • Investors Count 4

All 7 funding rounds of Prosetta Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Nov 2015$31.1MSeries D––
Jul 2012$2.04MSeries B––
–
Jun 2012$441,743Grant––
Jun 2012$441,743Grant––
Apr 2011$253,958Grant––
May 2010$451,580Grant––
May 2007$2MSeries A––
–
Valuation history

4 investors in total: 4 institutional.

Investors in Prosetta Biosciences

Prosetta Biosciences has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Takeda Pharmaceuticals, HHS and Alger.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
ESG investments are managed by this venture capital firm.
1964alger.comNew York, United States
Takeda Pharmaceuticals is engaged in developing innovative medicines globally.
1781takeda.comTokyo, Japan
Public health and human services are overseen by HHS.
1953hhs.gov
Administers health care and support for military personnel and operations.
health.milFalls Church, United States
Premium access

Investor details for Prosetta Biosciences

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Prosetta Bio-Conformatics Private Limited (Prosetta Biosciences)

Prosetta Bio-Conformatics Private Limited is the primary company behind Prosetta Biosciences. The board of Prosetta Bio-Conformatics Private Limited currently have 4 directors; the longest-serving is Vishwanath Rao Lingappa, appointed in 2004.

DirectorDesignationAppointedTenureEntity
Vishwanath Rao Lingappa
DIN 02272426
Director03 Mar 200422 yrs 8 moProsetta Bio-Conformatics Private Limited
Karl Michael Manheim
DIN 02234843
Director03 Mar 200422 yrs 8 moProsetta Bio-Conformatics Private Limited
Nisrani Hosmane Ramakrishna
DIN 02744329
Director30 Jun 200719 yrs 4 moProsetta Bio-Conformatics Private Limited
Mahadevappa Dharma Prasad
DIN 02327449
Director30 Jun 200719 yrs 4 moProsetta Bio-Conformatics Private Limited

People of Prosetta Biosciences

8 people are tracked at Prosetta Biosciences (2 in leadership, 6 in board & advisors).

NameRoleGroup
CEO & CTOLeadership
Dmitry T.
Director of ITLeadership
DirectorBoard & advisors
David N. Keys
DirectorBoard & advisors
Dale Bredesen
DirectorBoard & advisors
Charles M. Parrish
DirectorBoard & advisors
Hal Liebes
DirectorBoard & advisors
Thomas Higgins
ChairmanBoard & advisors
Premium access

Complete people profiles for Prosetta Biosciences

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Financials of Prosetta Biosciences

Figures of Prosetta Bio-Conformatics Private Limited, the primary company behind Prosetta Biosciences, for FY 2024. Revenue was ₹1.18 Cr (-11% year on year). Net profit was ₹10.3 Lakh (9% margin). EBITDA was ₹28.5 Lakh (24% margin). Revenue has grown at a compounded annual rate of -7% over three years and -8% over five years.

  • ₹1.18 CrRevenue · FY 2024 · -11% YoY
  • ₹10.3 LakhNet profit · 9% margin
  • ₹28.5 LakhEBITDA · 24% margin
  • ₹21.8 LakhPaid-up capital
  • -7%Revenue CAGR, 3 years
  • -8%Revenue CAGR, 5 years

Balance sheet, profit and loss, cash flow and ratios of Prosetta Bio-Conformatics Private Limited are on its company page.

Premium access

Detailed financial statements for Prosetta Biosciences

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Timeline of Prosetta Biosciences

3 dated milestones of Prosetta Biosciences across 12 years, from founding to its latest funding, stage changes and deals.

  1. Founded Prosetta Biosciences is founded.
  2. Funding First funding round of $2.0M.
  3. Funding Latest funding round, Series D, of $31.1M.

Competitors of Prosetta Biosciences

Prosetta Biosciences has 3 listed competitors in our database, 2 of them funded. They include Moderna, Adaptive Biotechnologies and Novavax.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
modernatx.com2010Cambridge, United States$2.78B1,312
mRNA-based therapeutics for diseases including cancer and infections are developed.
adaptivebiotech.com2009Seattle, United States$419.15M609
Clinical diagnostics and drug discovery for immune diseases are provided.
novavax.com1987Gaithersburg, United States184
Novel vaccines are developed using nanoparticle and matrix adjuvant technology.
Premium access

Detailed competitors of Prosetta Biosciences

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Prosetta Biosciences

The website of Prosetta Biosciences (prosetta.com) receives about 2.2K visits a month.

  • Monthly visits
    2.2K

    ▲ 5.9% vs previous month

Top companies in Infectious Diseases

3 companies that operate in the same segment as Prosetta Biosciences (Infectious Diseases) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Developer of molecular diagnostic testing solutions
1996Sunnyvale, California, United StatesUSD 19.1 MUSD 87.11 M4,647
Therapeutics for drug-resistant bacterial infections are developed.
2013Cambridge, Massachusetts, United StatesUSD 114.7 MUSD 59.62 M32
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Frequently Asked Questions about Prosetta Biosciences

Prosetta Biosciences was founded in 2003 and raised its 1st funding round 4 years after it was founded.

Prosetta Biosciences is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.

Prosetta Biosciences is a funded company, having raised a total of $35.14M across 7 funding rounds to date. The company's 1st funding round was a Series A of $2M, raised on May 2007.

The primary company behind Prosetta Biosciences, Prosetta Bio-Conformatics Private Limited, reported revenue of β‚Ή1.18 Cr for FY 2024, down 11% year on year.

Developer of antiviral and other therapeutics using proprietary drug discovery platform. The companys research is based on its proprietary cell-free protein synthesis or CFPSS drug discovery platform allows for the identification of small molecule drugs, which may be missed by traditional pharma screening methods. The company has successfully produced potent compounds which display activity against multiple strains of many viral families including lead series of molecules that are effective antiviral agents against influenza, HIV, and HCV.

Prosetta Biosciences's top competitors include Moderna, Adaptive Biotechnologies and Novavax.

Prosetta Biosciences offers Small Molecule Therapeutics.

Prosetta Biosciences has 4 investors. Key investors include Takeda Pharmaceuticals, HHS, Alger, and Military Health.

Prosetta Biosciences operates through Prosetta Bio-Conformatics Private Limited.

The legal entities of Prosetta Biosciences currently have 4 directors, including Vishwanath Rao Lingappa, Nisrani Hosmane Ramakrishna, Karl Michael Manheim and others.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available